The National Highway Traffic Safety Administration (NHTSA) has, on Wednesday, opened a defect investigation into the Tesla Model 3’s emergency door system, accordingThe National Highway Traffic Safety Administration (NHTSA) has, on Wednesday, opened a defect investigation into the Tesla Model 3’s emergency door system, according

U.S. regulators are investigating 179,071 Tesla Model 3 cars from 2022 over hidden emergency door releases

The National Highway Traffic Safety Administration (NHTSA) has, on Wednesday, opened a defect investigation into the Tesla Model 3’s emergency door system, according to a notice posted on its website that said the lever on these doors may be “hidden, unlabeled, and not intuitive to locate during an emergency.”

The review covers 179,071 Model 3 sedans from the 2022 model year, and comes after a petition filed by Kevin Clouse, a Tesla owner in Georgia, who said he was trapped inside his car when it caught fire in 2023.

“I was forced to climb to the back seat and break the rear passenger window with my legs to escape while the interior was burning,” said Kevin.

TeslaSource: NHTSA

NHTSA expands ongoing investigation into Tesla’s mountain of door issues

Just last September, the NHTSA opened a separate case into the Tesla Model Y after several reports of children getting stuck when the 12-volt battery died, since that makes the electric handles stop working.

The Model 3 and Model Y are the company’s best-selling cars, so these cases could impact a large group of drivers.

A Bloomberg investigation found that at least 15 people have died in the past decade in situations where Tesla doors didn’t open after a crash. Some of the deaths allegedly involved first responders unable to open the doors fast enough when the cars caught fire.

During the design phase for the Model 3, engineers flagged concerns about electric handles not working in an emergency. As previously reported by Cryptopolitan, those concerns were brought directly to Chief Executive Officer Elon Musk, who still chose to go with the same design, as long as a manual release was included.

Musk faced concerns years ago, but pushed ahead

The issue goes back to how Tesla builds its cars. The Model S, which launched in 2012, was the first model the company built from scratch. It came with flush door handles that slide out when touched. The design helped reduce wind drag and noise, but it also added complexity. If the power is cut, those electric handles don’t function.

Elon Musk admitted there were problems with these door sensors as early as 2013. “We’ve got quite a fancy door handle, and occasionally the sensor would malfunction,” he told analysts during a quarterly earnings call. “So you’d pull on the door handle, and it wouldn’t open. Obviously, it’s quite vexing for a customer.”

In 2021, Elon told analysts that the issue had been resolved. “Essentially, the door-handle incidents have gone to virtually zero.” But that’s not what Clouse and others are reporting in 2025.

After Clouse filed his petition last month, NHTSA started reviewing whether to launch a full recall. The agency hasn’t made a final decision yet, but the investigation is live. Bloomberg also confirmed details of Clouse’s 2023 fire incident, including the fact that he had to kick through a window to get out while the cabin filled with smoke.

Tesla shares dropped 0.7% at the close of the market on Christmas Eve, following a shortened session. The company has not issued a public response to the investigation. Clouse, meanwhile, is still waiting for answers.

Don’t just read crypto news. Understand it. Subscribe to our newsletter. It's free.

Market Opportunity
Union Logo
Union Price(U)
$0.002444
$0.002444$0.002444
-0.97%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26